Aslan’s change of course on eczema asset brings flexibility for future deals

Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the partnership's scope to give the biotech full commercial rights, is part of Aslan's broader intention to gain flexibility for potential deals in the future.

Although the latest deal is reminiscent of decisions by Aslan Ltd. (TPEx:6497; NASDAQ:ASLN) to renegotiate expanded rights agreements for other programs -- part of a shift in its overall business model -- CEO Carl Firth had previously signaled that ASLAN004 was an exception in its pipeline. Aslan had believed a restructured deal was unlikely for that program, and that it would instead seek a partnership once proof of concept was achieved...